Patient description: The patient is a 55 year old man visiting his primary care physician for lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow for the past 9 months. Further evaluation revealed: IPSS score : 15 Post-void residual: 70 mL Prostate volume (TRUS): 60 mL Prostate-specific antigen (PSA) level: 3.2 ng/mL 10 mL/sec of maximum flow rate when urine volume was 130 mL He is otherwise healthy only using Vit D 1000 units daily. His recent blood chemistry (3 days ago) was normal: Hgb: 13.5 g/dl WBC: 135000 /mm3 Plt: 350000 /ml PT: 11 second PTT: 35 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Prostate Cancer Participants must meet all of the following to be enrolled in this study. 1. Male aged 21 years or older. 2. Ability to provide signed informed consent and willingness to comply with protocol requirements. 3. Participants must agree to use condoms for a period of seven days after each injection, if engaged in sexual activity. Additional for Patients: i. Histologic diagnosis of prostate cancer by validated medical history. (Pathology report, if available). ii. Evidence of metastatic disease demonstrated by a documented abnormal bone scan, CT scan, or MRI plus a Clinical Stage 3 and Gleason Score ≥ 8. iii. Karnofsky performance is ≥ 60. Additional for Healthy Volunteers: i. PSA laboratory assessment within normal range (PSA < 4 ng/ml). ii. Normal findings on a digital rectal examination. iii. Hemoglobin and hematocrit within normal range  Participants must NOT meet any of the following to be enrolled in this study. 1. Received an investigational compound and/or medical device or is part of an investigational study within the past 30 days before enrollment into this study. 2. Subject was administered a radioisotope within 5 physical half lives of that radioisotope prior to study enrollment 3. Have any medical condition or other circumstances which, in the opinion of the Investigator, would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations. 4. Participant is determined by the Investigator to be clinically unsuitable for the study. 5. Serum creatinine ≥ 2.0 mg/dl 6. Total bilirubin ≥ 2.0 mg/dl 7. Liver transaminases ≥ 1.5 x ULN 8. Platelet count < 150,000/mm3 9. Absolute neutrophil count (ANC) < 2,000/mm3. 10. Hematocrit < 30% or hemoglobin < 10 g/dl. 11. Abnormal coagulation profile (PT, PTT or INR) > 1.3 ULN unless on therapeutic anticoagulation. Additional for Patients: Patients will be excluded from the study if any of the following are observed: i. Androgen deprivation therapy or other forms of hormonal therapy not stable for a period of 14 days prior to screening. ii. Subject has received a permanent prostate brachytherapy implant within the last 3 months for 103Pd implants; or 12 months for 125I implants. iii. Subject on or expected to be starting cytotoxic chemotherapy during the study period. iv. Has had any other malignancies within the past year, other than basal or squamous cell carcinoma of the skin, diagnosis and location must be defined or be defined as clinically controlled or treated to complete response. Additional for Healthy Volunteers: Healthy Volunteers will be excluded from the study if any of the following are observed: i. Have had any malignancies within 5 years other than basal or squamous cell carcinoma of the skin. ii. History of known prostate adenocarcinoma, prostate surgery/biopsy, prostatitis and/or symptoms suggestive of or associated with possible prostatitis within 6 months of enrollment